Navigation Links
ActiViews Raised $5M Dollars, in a Round led by 7 Health
Date:9/30/2009

HERZELIYA, Israel, September 30 /PRNewswire/ -- Medical device start-up ActiViews Ltd. raised $5M million in an investment round led by 7 Health Ventures. Previous investors: Ofer HiTech and Evergreen Venture Partners participated in the round as well.

ActiViews, founded in 2007, is developing optical guidance systems used in Computer Tomography (CT), fluoroscopy and Magnetic Resonance Imaging (MRI) procedures. ActiViews' first product, ActiSight(TM), improves minimally invasive oncology diagnosis, with future applications in guiding therapeutic devices to malignant targets. The ActiSight(TM) is CE approved

The company was founded by Pinchas Gilboa, the founder of SuperDimension. ActiViews CEO, Yuval Zuk, is the former CEO of Odin Medical Technologies. The company is located in Tirat Hacarmel, Israel and has 10 employees.

The funds will be used to set up a sales network in Europe and for obtaining marketing approval in the USA.

About 7 health Ventures:

7 Health Ventures is a professional venture capital fund dedicated to investing in Israeli and Israeli-related companies, developing healthcare technologies and products.

    http://www.7healthventures.com

    Company contact:

    Limor Sandach, Partner
    +972-9-9520214
    Limor@7healthventures.com


SOURCE 7 Health Ventures


'/>"/>
SOURCE 7 Health Ventures
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Surgeon Generals Call to Action to Prevent DVT/PE Praised by NATT as Turning Point
2. NYC Department of Healths Get Some NYC Condoms Sends Wrong Message and Misuses Tax Dollars, says MIM President Bob Peters
3. Globus Medical Raises $110 Million in Series E Financing Round
4. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
5. Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region
6. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
7. Mitchell, Military TBI Task Force Highlight the Importance of Traumatic Brain Injury Research; Mitchell Endorses Ground Breaking Traumatic Brain Injury Study
8. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
9. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
10. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
11. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 Neurim Pharmaceuticals ("Neurim") and ... exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... sleep disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic ... for children. The collaboration with Exeltis will help increase ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The global patient safety and risk management software ... geography. Patient safety has become a priority for ... developed significantly in the last decade and is currently on the ...
(Date:3/28/2017)... Md. , March 28, 2017 ... Dupixent (dupilumab) injection to treat adults with moderate-to-severe ... whose eczema is not controlled adequately by topical ... not advisable. Dupixent can be used with or ... Dupixent demonstrates our commitment to approving new and ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Immunotherapy has emerged as one of the most promising options for the ... next revolution in our fight against this complex disease. One of the most effective ... such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry tests ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
Breaking Medicine News(10 mins):